News Bayer’s Stivarga fast-tracked for liver cancer review Bayer’s cancer treatment Stivarga has been granted priority review status by the FDA for use as a second line treatment of unresectable hepatocellular carcinoma (uHCC).
News NICE says no to liver cancer drug Nexavar Liver cancer treatment latest earmarked for removal from CDF
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
